Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 702.50M | 705.50M | 668.60M | 478.60M | 428.00M |
| Total Depreciation and Amortization | 83.60M | 47.30M | 29.80M | 30.10M | 29.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 223.70M | 294.40M | 273.40M | 402.80M | 332.80M |
| Change in Net Operating Assets | 56.00M | -149.10M | -108.10M | -128.80M | -153.70M |
| Cash from Operations | 1.07B | 898.10M | 863.70M | 782.70M | 636.80M |
| Capital Expenditure | -26.10M | -27.70M | -32.40M | -34.00M | -43.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -2.36B | -2.36B | -- | -- | -- |
| Divestitures | 63.20M | 63.20M | 63.20M | -- | -- |
| Other Investing Activities | 1.62B | 1.43B | -815.60M | -230.40M | -236.10M |
| Cash from Investing | -705.60M | -891.20M | -784.80M | -264.40M | -279.80M |
| Total Debt Issued | 600.00M | 600.00M | -- | -- | -- |
| Total Debt Repaid | -600.00M | -600.00M | -- | -- | 0.00 |
| Issuance of Common Stock | 171.00M | 191.30M | 120.90M | 129.40M | 102.10M |
| Repurchase of Common Stock | -224.70M | -124.40M | -127.40M | -167.70M | -467.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.70M | -6.70M | -- | -- | -- |
| Cash from Financing | -60.40M | 60.20M | -6.50M | -38.30M | -365.60M |
| Foreign Exchange rate Adjustments | -- | -200.00K | 0.00 | 0.00 | -300.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 299.80M | 66.90M | 72.40M | 480.00M | -8.90M |